New vaccine trial aims to protect african babies from severe diarrhea
NCT ID NCT06663436
Summary
This study tested a 2-dose version of an experimental Shigella vaccine in healthy African infants. The goal was to see if this simpler schedule safely triggers a strong immune response to protect against Shigella, a bacteria that causes serious diarrhea. Researchers enrolled 200 infants around 9 months old to compare the vaccine's safety and effectiveness.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIARRHOEA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Kericho, 20200, Kenya
Conditions
Explore the condition pages connected to this study.